Clinical trials: With/Without Diabetes Mellitus, Type 2
Obesity and Type 2 Diabetes
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2…
- Trial name
- RESOLVE-1 (NCT07055516)
- Testing
- NT-0796
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rezera (formerly NodThera Limited)
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Primary Objective: To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in Chinese patients with type 2 diabetes (T2D) who have inadequate glycemic control on metformin alone…
- Trial name
- NCT03761134
- Testing
- sotagliflozin (SAR439954), metformin, sulfonylurea
- Where
- 40 sites in China
- Volunteers
- 377 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06972472
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.
- Trial name
- NCT00521690
- Testing
- insulin detemir
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study With InnoLet® in Daily Clinical Practice
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492959
- Testing
- insulin human
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.
Diabetes Mellitus, Type 2, Overweight
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal.
- Conditions
- Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT07299084
- Testing
- Tirzepatide
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM), Food Effect
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Food Effect, Safety and Tolerability, Obesity
- Trial name
- NCT07098663
- Testing
- MKP10241
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Mankind Pharma Limited
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in…
- Trial name
- NCT01486966
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2…
- Trial name
- NCT06643728
- Testing
- Bimagrumab, Tirzepatide
- Where
- 12 sites in United States
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Periodontal Disease
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age
The purpose of this study is to learn about the interactions of markers of type 2 diabetes (T2DM) and periodontitis (PD). Study VPE00001 is a multi-center cross-sectional study.
- Trial name
- NCT06582056
- Testing
- Investigational Procedure
- Where
- 4 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company